Date: 2016-09-12
Type of information: R&D agreement
Compound: Yeliva™ (ABC294640)
Company: Redhill Biopharma (Israel) Stanford University School of Medicine (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: enzyme inhibitor/sphingosine kinase-2 (SK2) inhibitor. ABC294640 is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anti-cancer and anti-inflammatory activities, targeting a number of potential inflammatory, oncology and gastrointestinal indications. By inhibiting the SK2 enzyme, ABC294640 blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid that promotes cancer growth and pathological inflammation. ABC294640 has completed multiple successful pre-clinical studies in inflammatory, GI, radioprotection and oncology models, as well as a Phase I clinical study in cancer patients with advanced solid tumors.
Disease: mucositis in head and neck cancer patients undergoing therapeutic radiotherapy
Details: * On September 12, 2016, RedHill Biopharma announced a research collaboration with Stanford University School of Medicine for the evaluation of RedHill’s proprietary Phase II-stage drug, Yeliva™ (ABC294640).
The research collaboration is intended to complement RedHill’s planned Phase Ib clinical study to evaluate Yeliva™ as a radioprotectant for prevention of mucositis in head and neck cancer patients undergoing therapeutic radiotherapy.
As part of the collaboration, Stanford will evaluate the effect of Yeliva™ on mucositis reduction and tumor control in a murine model of head and neck cancer. Yeliva™ will be administered in combination with a chemotherapy agent and radiotherapy, similar to the design of RedHill’s planned radioprotectant Phase Ib clinical study with Yeliva™, expected to run in parallel with the Stanford research collaboration. Results from the research collaboration are expected in mid-2017.
The Stanford research collaboration is led by Dr. Quynh-Thu Le, MD, a radiation oncologist, Chair of the Stanford Radiation Oncology Department, Co-Director of the Radiation Biology Program of the Stanford Cancer Institute and the Chair of the Head and Neck Cancer Committee of the NRG Oncology Group, part of the National Cancer Institute (NCI) supported National Clinical Trial Network (NCTN).
Financial terms:
Latest news:
